11.Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease.PR Newswire.25.10.2023. 12.CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel(exa-cel)for Severe Sickle Cell Disease...
11.Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease.PR Newswire.25.10.2023. 12.CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel(exa-cel)for Severe Sickle Cell Disease...
11.Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease.PR Newswire.25.10.2023. 12.CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel(exa-cel)for Severe Sickle Cell Disease...
11.Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease.PR Newswire.25.10.2023. 12.CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel(exa-cel)for Severe Sickle Cell Disease...
11.Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease.PR Newswire.25.10.2023. 12.CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel(exa-cel)for Severe Sickle Cell Disease...
11.Akebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease.PR Newswire.25.10.2023. 12.CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel(exa-cel)for Severe Sickle Cell Disease...
Sustol NDA Resubmission Accepted by FDALea EslavaKimPharmD
The US Food and Drug Administration (FDA) has accepted Ardelyx’s resubmitted New Drug Application (NDA) for XPHOZAH (tenapanor) to control serum phosphate in adult patients with chronic kidney disease on dialysis who have had an insufficient response or intolerance to a phosphate binder therapy....
作者: FDA Accepts NDA Resubmission for SPN-830 Apomorphine Infusion Device. PDUFA 02/01/25 $Supernus(SUPN)$阿扑玛啡cns#biotech##Seeking#
Axsome Therapeutics: FDA Accepts NDA Resubmission for AXS-07 for Acute Treatment of Migraine Patient Care (Online)Meglio, Marco